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Abstract 
This paper briefly summarizes the results of a long-term, open pharmacotherapy trial in 16 patients with well-characterized 
mitochondrial disease. Outcome measures included repeated clinical evaluation, 3~ P-NMR spectroscopy and near-infrared spectroscopy. 
Treated patients appeared to survive longer with less functional disability and medical complications than typically seen in clinical 
practice. 
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1. Introduction 
Mitochondrial diseases are degenerative disorders which 
result from progressive decline in the ability to supply 
cellular energy requirements. The mitochondrial diseases 
include myopathies, encephalopathies and encephalomy- 
opathies, and are characterized by clinical, biochemical 
and genetic heterogeneity. From a clinical perspective, the 
phenotype can vary extensively, and depends primarily on 
the severity of mitochondrial dysfunction, the patient's age 
at clinical presentation, and the tissues primarily involved 
in the disease. Progressive multisystem involvement is 
common, and those tissues requiring a large supply of ATP 
(e.g., central nervous system, muscle, retina, liver and 
kidney) are most susceptible to clinically apparent dys- 
function (Table 1). 
The most commonly encountered mitochondrial dis- 
eases in clinical practice are mitochondrial myopathies. In
these disorders, most patients present during the adult 
years with progressive ptosis, external ophthalmoplegia, 
muscle weakness and fatiguability. Multisystem dysfunc- 
tion consisting of progressive neurosensory hearing loss, 
pigmentary retinal deterioration and peripheral neuropathy 
are not uncommon. The majority of these patients remain 
productive for many years and die from causes unrelated 
to their primary disease, i.e., ischemic cardiac or cere- 
brovascular disease. Kearns-Sayre syndrome (KSS) is a 
mitochondrial encephalomyopathy which typically pre- 
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sents in the pediatric age group and is characterized by 
progressive ptosis, external ophthalmoplegia, cardiac con- 
duction defects, ataxia, short stature, pigmentary retinopa- 
thy, endocrinopathies, progressive dementia, elevated cere- 
brospinal fluid protein and neurosensory hearing loss. De- 
fects of cardiac conduction are progressive in nature and 
may result in sudden death; placement of a prophylactic 
cardiac pacemaker is frequently required. The majority of 
patients are significantly disabled by their disease, experi- 
ence a progressive decline in clinical status and die from 
causes directly related to their disease, e.g., cardiac failure. 
Mitochondrial encephalomyopathy with lactic acidosis and 
stroke-like episodes (MELAS) is characterized by non- 
vascular stroke-like pisodes, migrainous headaches, lactic 
acidosis, epilepsy and progressive dementia. The clinical 
course is unpredictable, patients become progressively dis- 
abled in a step-wise fashion and the prognosis is character- 
istically poor. Most patients uccumb to the disease or a 
complication directly related to the disease in a short 
period of time. Mitochondrial encephalomyopathy with 
ragged red fibers (MERRF) is an infrequently encountered 
mitochondrial encephalomyopathy c aracterized by promi- 
nent myoclonus, epilepsy, cerebellar dysfunction and pro- 
gressive dementia. Gastrointestinal dysfunction is not un- 
common. The majority of these patients die from status 
epilepticus or complications related to their seizure disor- 
der. 
Although new mitochondrial syndromes are frequently 
described, mitochondrial myopathy, KSS, MELAS and 
MERRF are of most significance to the clinician due to the 
fact that they are more commonly encountered than other 
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Table 1 
Multisystem involvement in mitochondrial disease 
System Clinical/laboratory features 






seizures, dementia, neurosensory hearing loss, myoclonus, 
cerebellar dysfunction, stroke-like pisodes 
ocular myopathy (ptosis, external ophthalmoplegia), 
proximal myopathy with fatiguability, cardiomyopathy 
pigmentary retinopathy 
impaired hepatic function 
renal tubular dysfunction 
neuropathy, impaired intestinal absorption, endocrinopathy 
(glucose intolerance, hormonal insufficiency) 
mitochondrial diseases. Several recent clinical reviews of 
mitochondrial diseases are recommended for the interested 
reader [1-3]. Significant advances have been made in 
mitochondrial genetics and several disease specific mito- 
chondrial DNA mutations have been identified [4,5]. 
Growing recognition of mitochondrial diseases and their 
clinical diagnosis have necessitated the search for effective 
therapy. Despite the poor therapeutic potential associated 
with the term 'degenerative disease', understanding of the 
pathophysiology of mitochondrial disease has facilitated 
efforts to develop effective clinical therapy. It is now 
recognized that a significant pathophysiologic consequence 
of mitochondrial dysfunction i cludes failure of energy-de- 
pendent ionic balance, with subsequent increase in intra- 
cellular calcium content and initiation of lipolysis and 
proteolysis [6-8]. Accumulation of lactic acid and partial 
reduction of respiratory activities leads to the production 
of reactive oxygen species. These pathophysiologic conse- 
quences have prompted the use of antioxidants, electron 
transfer mediators (which by-pass the inhibitory site), en- 
zyme cofactors and agents which block calcium-activated 
degrading pathways in clinical practice [9-14]. Large dou- 
ble-blind, clinical trials of potentially beneficial corn- 
pounds have been hindered by the rarity of all of the 
mitochondrial diseases, their heterogeneous nature, the 
unpredictable nature of the clinical course, and the lack of 
reliable clinical outcome measures. 
In this paper, the results of a long-term pharmacother- 
apy trial in 16 patients with well-characterized mitochon- 
drial myopathy and encephalomyopathy are presented. 
2. Clinical pharmacotherapy trial 
2.1. Patient selection 
Sixteen patients were selected from a large referral 
population of patients with degenerative mitochondrial dis- 
ease. Those patients with mitochondrial myopathy, KSS, 
MELAS or MERRF who lived within a distance which 
would permit frequent clinical follow-up, were included in 
the study. The patient population is characterized in Table 
2. There were 4 patients with a mitochondrial myopathy, 4 
with KSS, 6 with MELAS and 2 with MERRF. Patients 
ranged in age from 7 to 59 years, (6 were pediatric). There 
were 7 male patients and 9 females. 
Table 2 
Clinical characteristics of study population 
Patient # I.D. Clinical syndrome Sex Age at onset of treatment (y) 
1. P.R. mitochondrial myopathy M 49 
2. V.I. mitochondrial myopathy F 59 
3. C.M. mitochondrial myopathy F 51 
4. H.M. mitochondrial myopathy F 54 
5. S.J. KSS F 7 
6. Y.M. KSS M 23 
7. D.C. KSS F 25 
8. M.R. KSS M 19 
9. B.M. MELAS M 34 
10. B.L. MELAS F 31 
11. M.L. MELAS M 19 
12. A.M. MELAS F 31 
13. K.B. MELAS F 33 
14. F.T. MELAS M 15 
15. K.J. MERRF M 19 
16. W.P. MERRF F 17 
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2.2. Biochemical studies of isolated skeletal muscle mito- 
chondria and identification of sites(s) of impairment along 
the respiratory chain 
Thirteen of the patients underwent muscle biopsy for 
isolation and analysis of fresh skeletal muscle mito- 
chondria. All 16 patients had prior muscle biopsies per- 
formed which revealed histochemical evidence of mito- 
chondrial disease before referral to our center. Mitochon- 
drial preparations were isolated and characterized as de- 
scribed by Makinen and Lee [15] and Lee et al. [16,17]. 
The respiratory and phosphorylation activities of fresh, 
isolated skeletal muscle mitochondria from patients with 
mitochondrial rnyopathy are briefly summarized in Table 
3. All patients (#1-4)  had decreased State 3 rates with 
both pyruvate + malate and succinate (+ rotenone) as sub- 
strates, although the rates with pyruvate + malate were 
more significantly impaired. However, with the exception 
of patient #3 the capacities of energy coupling as reflected 
by the respiratory control index (RCI), and efficiencies of 
phosphorylation (ADP/O)  were within the normal range. 
Part of these studies have been briefly communicated [18]. 
The data from the four patients with KSS (#5-8)  are 
shown in Table 3. In all 4 patients the State 3 respiratory 
rates with NAD-linked substrate and succinate ( + rotenone) 
were severely impaired. The cytochrome oxidase activity 
(data not shown) was also slower than that of controls, but 
was considerably faster than the rate with either succinate 
or NAD-linked substrates [19]. This indicated that the 
depressed respiratory rates with succinate and NAD-linked 
substrates could not be due to impairment of cytochrome 
oxidase. Cytochrome analyses revealed a severe deficiency 
of cytochrome a + a~ (= 30% of control) and an excess of 
c cytochrome (= 130% of control). Analyses of the steady 
state reduction kinetics revealed the rate-limiting step in 
the transfer of electrons from reduced substrates to oxygen 
was on the path between cytochrome c and cytochrome 
oxidase [19]. The data obtained from fresh intact skeletal 
Table 3 
Respiratory and phosphorylating activities of isolated skeletal muscle mitochondria in patients with mitochondrial myopathy, KSS, MELAS and MERRF 
Substrates Respiratory rate RCI ADP/O 
(nAtoms O/min  per mg prot.) a 
Pyruvate + malate 
Patient # 1 076.9 4.2 
Patient #2 114.7 5.7 
Patient #3 45.6 1.5 
Patient #4 97.4 2.8 
Patient #5 b 32.0 2.8 
Patient #6 60.4 3.0 
Patient #7 68.4 3.7 
Patient #8 40.9 1.6 
Patient #9 81.5 4.7 
Patient # l0 52.6 3.2 
Patient # 11 19.9 1.6 
Patient # 15 111.6 4.5 
Patient # 16 61.0 2.6 
Controls (n = 6) 154 +_ 8 4.2 
Succinate ( + rotenone) 
Patient # 1 84.6 2.7 
Patient #2 166.3 3.4 
Patient #3 129.1 1.9 
Patient #4 132.2 1.9 
Patient #5 b 41.0 -- 
Patient #6 91.0 2.1 
Patient #7 94.7 1.8 
Patient #8 55.3 - 
Patient #9 174.6 3.5 
Patient # 10 151.4 2.9 
Patient # I l 144.8 3.1 
Patient # 15 161.5 3.7 
Patient #16 233.3 2.4 





























The respiratory rates and P/O (ADP/O) ratios of the mitochondrial preparations using various substrates were determined polarographically. The reaction 
mixture consisted of 150 mM sucrose, 25 mM Tris-CI, 10 mM phosphate (pH 7.4) and 0.7 to 1.0 nag skeletal muscle mitochondria. Final volume: 1.0 ml; 
temperature: 30 ° C. Other substrates are as indicated: 5 mM pyruvate, 2.5 mM malate, 5 mM succinate and 2.5 /zM rotenone. The respiratory rate refers to 
the State 3 rate which was initiated upon the addition of 258-267/zM ADP. Patient numbers correspond to Table 2. 
a Values for controls are the mean + S.E. 
b Fresh autopsy tissue; RCI: respiratory control. 
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muscle mitochondria in patients with MELAS (patients 
#9-11)  and MERRF (patients #15 and 16) are summa- 
rized in Table 3. With the exception of patient # 11, all 
patients showed mild-severe impairment of NAD-linked 
substrate oxidation. The rates of succinate oxidation were 
within the normal range. The cytochrome contents were 
also comparable to controls, although a mild deficiency in 
cytochrome b (= 60% of control) was seen with patient 
# 11. A portion of these studies have been briefly commu- 
nicated [20,21 ]. 
The data clearly demonstrated that all 4 mitochondrial 
diseases shared one common biochemical abnormality. 
Electron transfer associated with Complex I was impaired 
to a varying degree. Those patients with KSS were most 
severely affected while those with mitochondrial myopathy 
were much less affected. However, in all cases, the mito- 
chondria were tightly coupled and possessed normal phos- 
phorylating efficiencies with both succinate and NAD-lin- 
ked substrates. 
2.3. Design of therapeutic treatment 
The general recommendations made to all patients were 
to avoid extremes of temperature and overexercise. Fever, 
infection and seizures were promptly treated, adequate 
hydration was maintained, and drugs known to compro- 
mise mitochondrial function (e.g., anticonvulsants such as 
dilantin and phenobarbital nd antibiotics uch as tetra- 
cycline and chloramphenicol) were avoided. 
Menadiol sodium diphosphate (vitamin K 3) (20-60 
mg/day, in divided doses), ascorbic acid (vitamin C) (1 
g/twice per day), ce-tocopherol (vitamin E) (200 IU/twice 
per day), (Coenzyme Q10 (30-120 mg/day, in divided 
doses), and methylprednisolone (2-16 mg/every other 
day, in divided doses) were administered. Vitamins K 3 and 
C have been used as electron transfer mediators to circum- 
vent reduced activity of Complex III. The effective com- 
bined use of vitamins K 3 and C has been described in the 
literature [13,22]. Vitamin C, Vitamin E and Coenzyme 
Q10 are used for their antioxidant properties. Effective use 
of vitamin E [3,9,10] and Coenzyme Ql0 [3,10,12] have 
been described. Low dosages of glucocorticoids ( uch as 
methylprednisolone) have been shown to result in an in- 
crease in muscle strength and decrease in serum lactate 
[23,24] and to promote the synthesis of a protein inhibitor 
of phospholipase (lipocortin) [25]. Methylprednisolone has 
been effectively used in the treatment of mitochondrial 
diseases [3,10]. 
All patients were treated and clinically evaluated every 
2-4 weeks. 
2.4. Evaluation of the efficacy of therapeutic ntervention. 
3 ~ P-NMR, NIRS and clinical/laboratory examination 
Patients were carefully monitored for side effects of 
pharmacotherapy (e.g., hyperglycemia, bleeding disorder, 
infection, liver or renal dysfunction). During outpatient 
follow-up visits, patients and families were interviewed by 
the same neurologist. A complete physical and neurologic 
examination was performed. Evidence based on physical 
examination or laboratory study of clinical deterioration 
was noted, current herapy was reviewed, and if considered 
suitable, recommendations were made for changes in ther- 
apy. Anticonvulsant levels, serum creatine phosphokinase 
(CPK), lactic acid levels and relevant laboratory studies 
were routinely performed. 
During the course of the study, 5 patients were sent to 
the University of Pennsylvania toundergo evaluation using 
31P-NMR spectroscopy. All patients underwent a baseline 
31P-NMR spectroscopic evaluation. Pharmacotherapy was 
Table 4 
Clinical outcome 
Patient Clinical Time Major Current 
# syndrome followed medical clinical 
(y) events ~ status 
1. mitochondrial myopathy 13 0 functional 
2. mitochondrial myopathy 10 0 functional 
3. mitochondrial myopathy 6 0 gainfully employed 
4. mitochondrial myopathy 4 0 functional 
5. KSS 3 1 deceased 
6. KSS 7 0 functional 
7. KSS 8 0 functional 
8. KSS 2 1 deceased 
9. MELAS 8 0 deceased 
10. MELAS 4 1 deceased 
11. MELAS 0.5 3 deceased 
12. MELAS 5 1 deceased 
13. MELAS 2 3 deceased 
14. MELAS 1 2 deceased 
15. MERRF 15 0 deceased 
16. MERRF 1 3 deceased 
Major medical events are defined as medical events related to the primary diagnosis which resulted in hospitalization of the patient, (e.g., uncontrolled 
seizures, organ failure, systemic infection). 
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administered immediately prior to 3~ P-NMR evaluation to 
determine whether any objective improvement occurred 
with treatment. Ten patients were examined using near-in- 
frared spectroscopy (NIRS) as previously described [26]. 
Pharmacotherapy was again administered immediately be- 
fore the test to determine whether improvement could be 
objectively demonstrated. 
The study performed at the University of Pennsylvania 
to evaluate whether 31P-NMR spectroscopy did not reveal 
acute changes associated with the administration of phar- 
macotherapy. However, the study did document the utility 
of 31P_NMR in screening patients with muscle weakness 
for mitochondrial disease [27]. NIRS was also used as an 
outcome measure of the efficacy of pharmacotherapy. 
Although the efficacy study was inconclusive, due to the 
small number of patients examined, the data did support 
the usefulness of NIRS as a screening tool for patients 
with possible mitochondrial myopathy [28]. 
2.5. Clinical outcome 
No patient experienced any significant deleterious side 
effect of the pharmacotherapy. Repeated blood levels of 
CPK and lactic acid were not predictive of clinical out- 
come. Table 4 summarizes the clinical outcome data. 
Cases #5, 8 and 11-16 were pediatric patients. With the 
exception of patient # 15, all patients died fairly soon after 
diagnosis. They were hospitalized more frequently than the 
adults and showed severe biochemical abnormalities on 
biopsy. Cases #5, 8, 11 and 12 died of cardiac failure, 
patient # 10 of renal failure and cases #13, 14 and 16 died 
due to complications of status epilepticus. The cause of 
death of cases #9 and 15 was uncertain although a cardiac 
etiology was presumed. Case #16 was totally noncompli- 
ant with her therapy. Among the adult patients, those with 
mitochondrial myopathy remained functional. Two KSS 
patients are still alive and functional, although both re- 
quired cardiac pacemaker placement. Among the adult 
MELAS patients, case # 13 developed repeated episodes of 
status epilepticus; the last episode was not responsive to 
anticonvulsant therapy and she died. Cases #9, 10 and 12 
survived longer than expected considering the typically 
poor prognosis associated with their diagnosis. They had 
few complications related to their disease and were able to 
lead a comfortable life until they succumbed to their 
disease. All 3 of these patients died within a 6 month 
period after the oral form of K3 was taken off the market 
due to limited public demand. All patients were given oral 
phytonadione (Vitamin Ki) in similar dosages after the 
oral form of K 3 was discontinued. 
3. Conclusion 
The results of this long-term follow-up study are en- 
couraging. The patients appeared to survive longer with 
less functional disability and medical complications than 
typically seen in clinical practice. Those patients who had 
less severe mitochondrial impairment (based on biochemi- 
cal analysis), who were compliant with their therapy and 
were treated early in the course of their disease lived 
longer, were more functional and had fewer medical com- 
plications of their disease. 
There is no question that therapeutic drug trials are 
difficult to conduct in patients with mitochondrial diseases. 
The diseases are rare, heterogenous and short-term, objec- 
tive measures which are predictive of outcome have not 
been identified. 31P-NMR and N1RS deserve further evalu- 
ation in larger patient populations as the patient can serve 
as their own control and the results of intervention are 
objective. 
More complete understanding of the pathophysiology of 
mitochondrial disease clearly has facilitated the choice of 
potential pharmacotherapy. Electron transport mediators, 
free radical scavengers and drugs which block degrading 
pathways are logical pharmacotherapeutic choices. The 
development of new compounds, e.g., 21-aminosteroids 
[29], which are associated with few side effects and are 
more potent han the traditional glucocorticoids, i  encour- 
aging. Potential pharmacologic strategies have recently 
been reviewed by McIntosh [30]. 
Although therapeutic drug trials in mitochondrial dis- 
eases are inherently difficult to conduct, the long-term 
benefits are clearly worth the efforts. 
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